Guided Therapeutics GTHP.OB
Important Dates:
Sept 27, 2010: FDA's date of acceptance of the LightTouch PMA
March 7, 2011: FDA has additional questions on the clinical trials and "various technical issues." The company has 180 days to respond.
April 30 - May 4, 2011: LightTouch presentation at the American College of Obstetricians and Gynecologists Annual Clinical Meeting
May 9, 2011: LightTouch presentation at the EUROGIN (European Research Organisation on Genital Infection and Neoplasia) scentific meeting in Lisbon, Portugal
May 19 - 20, 2011 : FDA Ob/Gyn Devices Advisory Panel Meeting
Company Website: guidedinc.com
Press Releases: guidedinc.com
SEC Filings: sec.gov
Scheduled FDA advisory committee meetings: fda.gov
Agendas for advisory committee meetings: fda.gov
Slide presentation from a small cap conference Jan. 2011: guidedinc.com[Compatibility%20Mode].pdf
Shares Outstanding: 46,480,950 as of 11/01/2010
Shares Outstanding: 42,516,855 as of 07/30/2010
Shares Outstanding: 41,698,396 as of 04/30/2010
Shares Outstanding: 19,614,975 as of 02/25/2010
Shares Outstanding: 17,470,656 as of 11/09/2009
Shares Outstanding: 16,852,823 as of 08/14/2009
Shares Outstanding: 15,998,790 as of 05/22/2009
Shares Outstanding: 11,948,631 as of 04/09/2007
** On February 26, 2010, the Company held a special meeting of stockholders to approve an amendment to the Company’s certificate of incorporation to reclassify the series A convertible preferred stock into common stock and warrants to purchase shares of common stock. As a result, all 242,576 outstanding shares of series A convertible preferred stock and accrued dividends were reclassified into 8,084,139 shares of common stock and warrants to purchase an additional 2,799,327 shares of common stock. Upon this reclassification, approximately $9.1 million in outstanding 2007 Notes was automatically converted into 14.0 million shares of common stock.
Float: 28,292,659 as of 12/01/2010 per the company
Float: 31.21M as of 12/17/2010 per Yahoo
Float: 12.45M as of 3/17/2010 per Yahoo |
